Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
Investing.com - H.C. Wainwright has reiterated its Buy rating and $18.00 price target on Coya Therapeutics (NASDAQ:COYA), representing significant upside from the current price of $6.86. According to InvestingPro data, analyst targets range from $14 to $20, with a strong Buy consensus recommendation.
The firm noted that Coya submitted additional non-clinical data to the FDA in June 2025 to support the initiation of its COYA 302 Phase 2 trial in amyotrophic lateral sclerosis (ALS) patients. A decision from the FDA on the Investigational New Drug application is expected by August 29, 2025. InvestingPro analysis shows the company maintains a healthy current ratio of 7.43, with liquid assets well exceeding short-term obligations.
Upon IND acceptance and first patient dosing, Coya is positioned to receive milestone payments totaling $8.4 million from its strategic partner, Dr. Reddy’s Laboratories. The company also recently published research in Frontiers of Immunology linking inflammation and oxidative stress to Parkinson’s disease progression.
H.C. Wainwright highlighted several upcoming catalysts, including the publication of longitudinal biomarker data on neurofilament light chain and oxidative stress markers in ALS patients, and the release of new proteomics data from a completed Phase 2 study of low-dose interleukin-2 in Alzheimer’s disease.
Additional near-term milestones include top-line clinical data from an investigator-initiated trial in frontotemporal dementia, results for COYA 303 in an inflammatory animal model, and the filing of an IND for a COYA-302 Phase 2 trial in frontotemporal dementia patients later this year. The stock has shown strong momentum, gaining over 14% in the past week. Unlock more insights and 10 additional ProTips with InvestingPro.
In other recent news, Coya Therapeutics has made significant strides with its COYA-302 therapy, particularly in the treatment of amyotrophic lateral sclerosis (ALS). The company recently resubmitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for a Phase 2 clinical trial of COYA-302, incorporating additional non-clinical data as requested by the FDA. This trial is set to be a randomized, double-blind, placebo-controlled, multi-center study with a 24-week duration, followed by an open-label extension. In addition to this, Coya Therapeutics announced the issuance of a new U.S. patent for its liquid formulation of interleukin-2 (IL-2), which could potentially enhance treatment delivery and effectiveness.
Analyst firms have shown confidence in Coya Therapeutics, with BTIG maintaining a Buy rating and a $15 price target, and Lake Street Capital initiating coverage with a Buy rating and a $16 price target. H.C. Wainwright also reaffirmed its Buy rating, setting a higher price target of $18, following the patent announcement. The patent, identified as US 12,312,389 B2, is part of Coya’s strategy to bolster its intellectual property portfolio, which includes combination therapies with other biologics. These developments indicate a positive trajectory for Coya Therapeutics as it advances its clinical and research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.